A First-In-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of PF-06647263 In Adult Patients With Advanced Solid Tumors

Trial Profile

A First-In-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of PF-06647263 In Adult Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs PF 6647263 (Primary)
  • Indications Breast cancer; Fallopian tube cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results from part I (n=48) and part II (n=10) of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top